Guideline proposal for pharma companies to manage pharmacovigilance activities in digital media

• DOI: 10.33393/ao.2022.2401
• Publication Date: 2022-04-21T13:09:02Z
• Authors: Daniela Bernardini; Ilenia Bocchi; Stefano Bonato; Davide Bottalico; Valentina Calderazzo; Carmela Casino; Gian Nicola Casti...; Carla Cottone; Stefania Dellon; Ilaria Grisoni; Amanda Mattavelli; Giacomo Pirisino; Silvia Romano; Grazia Sirizzotti; Lisa Stagi; On behalf of the ...
• Keywords: Social media; Artificial intelligence; Pharmacovigilance; 03 medical and health sciences; 0302 clinical medicine; Digital activities; Adverse events; R; Medicine; 3. Good health

Internet has become a central part of our everyday lives. Digital media are integrated in our daily routines and play a critical role in the dissemination of public health information and disease prevention guidelines. For this reason, digital activities are becoming more and more impacting in pharma company activities and this is an increasing trend after the pandemic period. Managing digital activities from pharmacovigilance (PV) perspective may have challenges linked to correct assessment of the activities and application of PV rules: this was underlined in recent publications, where the need to have more specific guidelines linked to digital activities management was evidenced. Considering this scenario and the continuous evolution of the digital activities, the SIMEF PV working group decided to work on a proposal guideline to provide support to PV departments in pharma companies, suggesting a framework to manage sponsored digital activities (i.e., website, web apps, social media webpage, chatbots) impacting potential collection of adverse events (AEs). The purpose of this guideline is to provide useful instructions on how to manage PV requirements for digital activities, suggesting potential solutions for assessing initiatives, creating governance framework, conducting a correct vendor management, and suggesting practical approaches for AEs reporting and follow-up. The aim of this document is also to trigger a broader discussion among relevant stakeholders on which PV guidelines may be useful and appropriate considering this continuous evolving scenario.